Hls Therapeutics, Inc. · TSX:HLS
Hls Therapeutics — Q2 2024 Earnings Presentation
17 slides from Hls Therapeutics's earnings presentation, Aug 8, 2024
Slide 1: Q2 Fiscal 2024 Conference Call
Q2 Fiscal 2024 Conference Call August 8, 2024 Craig Millian, CEO John Hanna, Interim CFO TSX - HLS
Slide 2: Forward-Looking Statements
Forward-Looking Statements Certain statements in this presentation are “forward-looking statements”. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often, but not alwa
Slide 3: Q2 2024: Financial Highlights
Q2 2024: Financial Highlights Revenue: $14.5M HLS Canadian 11% product sales Adjusted EBITDA: $4.3M Adjusted EBITDA Cash from operations: 86% excluding royalties $2.5M Toronto Stock Exchange (TSX) - HLS Provided as part of an oral presentation and qualified by such, contains forward-looking statemen
Slide 4: Life-changing medicine for Treatment Resistant Schizophrenia
Life-changing medicine for Treatment Resistant Schizophrenia Toronto Stock Exchange (TSX) - HLS Provided as part of an oral presentation and qualified by such, contains forward-looking statements, actual results may vary materially; HLS disclaims any duty to update
Slide 5: Solid Q2 Performance with Momentum Heading into 2H'24
Solid Q2 Performance with Momentum Heading into 2H’24 US$10.1M US$7.6M Q2 revenue Q2 direct contribution to Adjusted EBITDA Canadian Q2 revenue up 5% YoY* U.S. Q2 revenue up 9% YoY *in Canadian dollars Goal is to grow North American Clozaril sales 1-2% annually, on average Toronto Stock Exchange (TS
Slide 6: A New Paradigm in the Treatment of Cardiovascular Risk
A New Paradigm in the Treatment of Cardiovascular Risk Toronto Stock Exchange (TSX) - HLS Provided as part of an oral presentation and qualified by such, contains forward-looking statements, actual results may vary materially; HLS disclaims any duty to update
Slide 7: Continued Growth in Prescribing
1,000 1,500 2,000 2,500 3,000 0 500 2020-02-21 2020-03-21 2020-04-21 2020-05-21 2020-06-21 2020-07-21 2020-08-21 2020-09-21 2020-10-21 2020-11-21 2020-12-21 2021-01-21 2021-02-21 2021-03-21 2021-04-21 2021-05-21 2021-06-21 2021-07-21 2021-08-21 2021-09-21 2021-10-21 2021-11-21 2021-12-21 2022-01-21
Slide 8: Vascepa Catalysts for 2H'24
Vascepa Catalysts for 2H’24 Bringing Primary Care Improving Growing the private Sales In-house Reimbursement payer segment Significant cost savings >90% national coverage for Enhanced financial assistance eligible private & public plan program launched in May Increased ownership and patients (recent
Slide 9: Royalty Portfolio
Royalty Portfolio Toronto Stock Exchange (TSX) - HLS Provided as part of an oral presentation and qualified by such, contains forward-looking statements, actual results may vary materially; HLS disclaims any duty to update
Slide 10: Sold Xenpozyme Royalty Interest Valued at up to $45.75M
Sold Xenpozyme Royalty Interest Valued at up to $45.75M Accelerates de-leveraging $13.25M upfront in cash Strengthens balance sheet $14.0M in potential sales-based milestone payments Reduces annual interest expense by $1.5M $18.5M potential milestone payment obligations assumed by DRI Places focus o
Slide 11: 2024 Guidance
2024 Guidance Toronto Stock Exchange (TSX) - HLS Provided as part of an oral presentation and qualified by such, contains forward-looking statements, actual results may vary materially; HLS disclaims any duty to update
Slide 12: 2024 Guidance
2024 Guidance Consolidated Clozaril revenue: ~$40M Adjusted EBITDA: revenue: $15.5-16.7M $58.5-59.7M Vascepa revenue: $17-$18M (C$22.5-$24.5M) Royalty revenue: $1.5-1.7M Vascepa goal: positive contribution to Adjusted EBITDA in Q4 2024 Toronto Stock Exchange (TSX) - HLS Provided as part of an oral p
Slide 13: Financial Review: Solid Foundation to support our growth
Financial Review: Solid Foundation to support our growth Toronto Stock Exchange (TSX) - HLS Provided as part of an oral presentation and qualified by such, contains forward-looking statements, actual results may vary materially; HLS disclaims any duty to update
Slide 14: Q2 2024: Financial Review
Q2 2024: Financial Review Revenue: $14.5M Operating Expenses Adjusted EBITDA: $4.3M 9% Excluding royalties 11% OPEX excluding cost of sales 86% AEBITDA excluding royalties 11% Canadian product sales* Direct to brand contribution 14% Selling & marketing $7.6M from Clozaril 21% Vascepa ($1.6)M Direct
Slide 15: Strong Balance Sheet
Strong Balance Sheet Summary Balance Sheet & Capitalization Subsequent to quarter-end (US$ millions) At Dec 31, 2023 At Jun 30, 2024 Made $14M debt payment Cash and Cash Equivalents 22.0 32.5 1 Senior Secured Term Loan and Revolver 88.5 84.9 Reduced term loan to ~ $71M Net Debt (Term Loan less Cash)
Slide 16: Q2 Summary
Q2 Summary 1 Solid growth from promoted products Clozaril and Vascepa 2 Delivering on our promise to reduce costs 3 Monetized Xenpozyme asset: strengthens financials and increases flexibility 4 Actions set HLS up for future growth and profitability Toronto Stock Exchange (TSX) - HLS Provided as part
Slide 17: Q2 Fiscal 2024 Conference Call
Q2 Fiscal 2024 Conference Call August 8, 2024 Craig Millian, CEO John Hanna, Interim CFO TSX - HLS